Perspective Therapeutics (CATX) Competitors $3.29 +0.25 (+8.22%) Closing price 04:00 PM EasternExtended Trading$3.28 -0.02 (-0.46%) As of 06:49 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrendsBuy This Stock CATX vs. MDXG, PLSE, INMD, IRMD, EMBC, TNDM, AXGN, SIBN, BVS, and AVNSShould you be buying Perspective Therapeutics stock or one of its competitors? The main competitors of Perspective Therapeutics include MiMedx Group (MDXG), Pulse Biosciences (PLSE), InMode (INMD), iRadimed (IRMD), Embecta (EMBC), Tandem Diabetes Care (TNDM), AxoGen (AXGN), SiBone (SIBN), Bioventus (BVS), and Avanos Medical (AVNS). These companies are all part of the "medical equipment" industry. Perspective Therapeutics vs. Its Competitors MiMedx Group Pulse Biosciences InMode iRadimed Embecta Tandem Diabetes Care AxoGen SiBone Bioventus Avanos Medical MiMedx Group (NASDAQ:MDXG) and Perspective Therapeutics (NYSE:CATX) are both small-cap medical companies, but which is the superior business? We will compare the two businesses based on the strength of their earnings, media sentiment, valuation, profitability, analyst recommendations, institutional ownership, risk and dividends. Does the media favor MDXG or CATX? In the previous week, Perspective Therapeutics had 5 more articles in the media than MiMedx Group. MarketBeat recorded 6 mentions for Perspective Therapeutics and 1 mentions for MiMedx Group. MiMedx Group's average media sentiment score of 1.66 beat Perspective Therapeutics' score of 0.28 indicating that MiMedx Group is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment MiMedx Group 1 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Very Positive Perspective Therapeutics 1 Very Positive mention(s) 1 Positive mention(s) 3 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Do analysts rate MDXG or CATX? MiMedx Group currently has a consensus price target of $12.00, indicating a potential upside of 67.83%. Perspective Therapeutics has a consensus price target of $12.56, indicating a potential upside of 281.63%. Given Perspective Therapeutics' stronger consensus rating and higher possible upside, analysts clearly believe Perspective Therapeutics is more favorable than MiMedx Group.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score MiMedx Group 0 Sell rating(s) 0 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 3.00Perspective Therapeutics 0 Sell rating(s) 1 Hold rating(s) 7 Buy rating(s) 3 Strong Buy rating(s) 3.18 Is MDXG or CATX more profitable? MiMedx Group has a net margin of 8.84% compared to Perspective Therapeutics' net margin of -4,096.66%. MiMedx Group's return on equity of 23.03% beat Perspective Therapeutics' return on equity.Company Net Margins Return on Equity Return on Assets MiMedx Group8.84% 23.03% 17.09% Perspective Therapeutics -4,096.66%-27.40%-23.16% Which has more risk and volatility, MDXG or CATX? MiMedx Group has a beta of 1.74, indicating that its stock price is 74% more volatile than the S&P 500. Comparatively, Perspective Therapeutics has a beta of 1.2, indicating that its stock price is 20% more volatile than the S&P 500. Which has stronger earnings & valuation, MDXG or CATX? MiMedx Group has higher revenue and earnings than Perspective Therapeutics. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioMiMedx Group$348.88M3.03$42.42M$0.2134.05Perspective TherapeuticsN/AN/A-$46.51MN/AN/A Do institutionals and insiders believe in MDXG or CATX? 79.2% of MiMedx Group shares are held by institutional investors. Comparatively, 54.7% of Perspective Therapeutics shares are held by institutional investors. 1.7% of MiMedx Group shares are held by insiders. Comparatively, 3.7% of Perspective Therapeutics shares are held by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock will outperform the market over the long term. SummaryMiMedx Group beats Perspective Therapeutics on 8 of the 14 factors compared between the two stocks. Get Perspective Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for CATX and its competitors with MarketBeat's FREE daily newsletter. Subscribe Now View SMS TermsBy entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding CATX and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NYSE and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart CATX vs. The Competition Export to ExcelMetricPerspective TherapeuticsSurgical & medical instruments IndustryMedical SectorNYSE ExchangeMarket Cap$244.33M$72.32M$5.76B$21.58BDividend YieldN/AN/A5.74%3.49%P/E RatioN/A10.7276.8630.17Price / SalesN/A40.66540.6754.68Price / CashN/A18.4137.1724.62Price / Book1.2312.1313.834.58Net Income-$46.51M-$25.86M$3.29B$1.00B7 Day Performance-2.66%-5.39%0.93%0.88%1 Month Performance-10.84%0.14%5.31%5.45%1 Year Performance-75.41%62.43%84.25%15.94% Perspective Therapeutics Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)CATXPerspective Therapeutics1.9671 of 5 stars$3.29+8.2%$12.56+281.6%-77.2%$244.33MN/A0.0070Analyst ForecastMDXGMiMedx Group3.5235 of 5 stars$6.94-2.8%$12.00+72.9%+12.8%$1.03B$348.88M33.05870Positive NewsPLSEPulse Biosciences4.1307 of 5 stars$14.52-3.8%$22.00+51.5%-20.0%$977.14MN/A-13.83140News CoverageInsider TradeHigh Trading VolumeINMDInMode2.9574 of 5 stars$14.83-3.3%$18.04+21.7%-14.0%$937.39M$401.56M6.00480Positive NewsIRMDiRadimed4.7948 of 5 stars$71.27-4.0%$72.00+1.0%+45.5%$906.55M$73.24M43.99110News CoveragePositive NewsInsider TradeShort Interest ↓EMBCEmbecta4.4588 of 5 stars$15.01-2.0%$19.00+26.6%-8.7%$877.94M$1.12B10.502,100Positive NewsTNDMTandem Diabetes Care4.2938 of 5 stars$12.27-4.1%$22.44+82.9%-71.7%$829.08M$940.20M-3.972,650Positive NewsAXGNAxoGen2.9182 of 5 stars$16.41-2.3%$26.00+58.4%+14.5%$755.07M$203.27M-164.08450SIBNSiBone3.8468 of 5 stars$15.70-3.8%$23.67+50.7%-6.2%$677.30M$167.18M-28.04350Positive NewsBVSBioventusN/A$7.23-0.7%N/AN/A$597.77M$564.14M14.541,200AVNSAvanos Medical2.3047 of 5 stars$12.23-1.5%N/A-51.0%$567.47M$687.80M-1.212,227 Related Companies and Tools Related Companies MDXG Alternatives PLSE Alternatives INMD Alternatives IRMD Alternatives EMBC Alternatives TNDM Alternatives AXGN Alternatives SIBN Alternatives BVS Alternatives AVNS Alternatives Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NYSE:CATX) was last updated on 9/18/2025 by MarketBeat.com Staff From Our PartnersCrypto Gets Official Government Backing—Here's the WinnerTrump Just Signed the GENIUS Act—One Coin is About to Explode We're at the BEGINNING of smart money really ...Crypto 101 Media | SponsoredNvidia CEO Makes First Ever Tesla AnnouncementWhile headlines focus on Tesla’s car sales, tech analyst Jeff Brown says the real story is Tesla’s role in a $...Brownstone Research | SponsoredForget NVDA. Put $1,000 into this stock nowA massive money shift is underway in the AI market. And it's opening up an extraordinary opportunity in a NEW ...Chaikin Analytics | SponsoredForget Tesla — This Tiny AI Stock Is Musk’s Real PlayWhile Wall Street focused on Tesla’s earnings, Elon Musk was quietly building a supercomputer so powerful it c...Behind the Markets | SponsoredTrump’s betrayal exposedTrump’s Final Reset Inside the shocking plot to re-engineer America’s financial system…and why you need to ...Porter & Company | SponsoredCollege grad makes $64,000 a monthA Wall Street legend just helped train our own proprietary AI system in the stock market (a project that took ...Stansberry Research | SponsoredDid you spot this in the Oval Office last week?When Tim Cook stood in the Oval Office last week, all eyes were on the "unique 24K gold gift" he presented to ...InvestorPlace | Sponsored$3,600 gold is nice ... but here’s what most gold bugs are missingGold just surged past $3,600, but Weiss Ratings expert Sean Brodrick says the real upside is in select gold st...Weiss Ratings | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Perspective Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Perspective Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
